<DOC>
	<DOC>NCT00302861</DOC>
	<brief_summary>This is a multi-center, open-label, single arm Phase 1/2 study evaluating the feasibility, safety, and tolerability of a series of 16 immunizations of Id-KLH with GM-CSF in patients with previously untreated B-CLL. The length of the controlled portion of the study is two years. The study will be conducted at investigative sites in the United States.</brief_summary>
	<brief_title>A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<criteria>Have signed a written informed consent BCLL diagnosis Rai Stage 0, I, or II Previously untreated Be able to watch and wait for approximately 8 months following submission of blood (or tissue) while IdKLH is being manufactured Antileukemia treatment prior to beginning immunization Antileukemia treatment other than IdKLH during immunizations Prior malignancy (excluding basal cell carcinoma and cervical carcinoma in situ) Pregnant or lactating Patients with known autoimmune disease (including previously treated autoimmune hemolytic anemia or immune thrombocytopenia) Participation in any other clinical trial in which an investigational agent is administered</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>B-Cll</keyword>
</DOC>